Healthcare Industry News: Hydroxyapatite
News Release - March 14, 2008
Biologics, Dermal Fillers are Key to Dermatological Drug Market GrowthNew York, March 14, 2008 --(HSMN NewsFeed)--Biologics and dermal fillers are driving significant growth in the prescription dermatological drug market, due in large part to new products and technology developments. The market was valued at $8.9 billion in 2006 and is expected to achieve a CAGR of 7% through 2011, lead by the anti-aging/photo-damage, hair treatment, psoriasis and skin cancer treatment segments, according to Kalorama Information’s new report Prescription Dermatological Drugs: Worldwide Market, 6th Edition.
“There are impressive new options for the treatment of aging skin, acne, psoriasis and a host of other conditions – including bio-engineered collagen, Hydroxyapatite fillers and new biologic agents,” notes Mary Ann Crandall, the author of the report. “These have moved from promising developments to viable treatment alternatives.”
New fillers include bio-engineered human injectable collagen, replacing bovine collagen which was plagued with short-lived results and allergic reactions, as well as hyaluronic acid gel, a new non-animal soft tissue filler that was recently approved in the United States. For longer-lasting results there is the new filler Hydroxyapatite with a methylcellulose vehicle and a recently approved permanent injectable called polymethylmethacrylate. A new medical grade form of silicone is also being studied to determine its safety and efficacy as a permanent filler.
With the advent of recombinant deoxyribonucleic acid technology and advances in microbiology and immunology, the biologics field is expanding rapidly and dermatology is a primary focus for the development of new agents. Biologics are expected to dominate the psoriasis market with a 70% market share by 2011, due to the introduction of several new biologic immune modulators. A number of other skin diseases are also good candidates for biologic therapy, namely atopic dermatitis and cutaneous T-cell lymphomas.
Kalorama Information’s report Prescription Dermatological Drugs: Worldwide Market, 6th Edition discusses critical issues and trends and provides updated market information for 2001 to 2011. The information presented is the result of interviews conducted with over 45 industry executives and data gathered through secondary research. The report can be purchased by visiting http://salesandmarketingnetwork.com/reports.php?ID=2496
About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.
Source: Kalorama Information
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.